Economic evaluation of rotavirus vaccination in children aged under five years in South Africa

dc.contributor.authorMohy, Ahmed
dc.contributor.authorPage, N.A. (Nicola)
dc.contributor.authorBoyce, Welekazi
dc.contributor.authorGomez, Jorge A.
dc.date.accessioned2024-04-19T11:19:39Z
dc.date.available2024-04-19T11:19:39Z
dc.date.issued2023-11
dc.descriptionDATA SHARING STATEMENT : The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.en_US
dc.description.abstractBACKGROUND AND OBJECTIVE Evidence on the economic value of rotavirus vaccines in middle-income countries is limited. We aimed to model the implementation of three vaccines (human rotavirus, live, attenuated, oral vaccine [HRV, 2 doses]; rotavirus vaccine, live, oral, pentavalent [HBRV, 3 doses] and rotavirus vaccine, live attenuated oral, freeze-dried [BRV-PV, 3 doses] presented in 1-dose and 2-dose vials) into the South African National Immunisation Programme. METHODS Cost and cost-effectiveness analyses were conducted to compare three rotavirus vaccines using a static, deterministic, population model in children aged <5 years in South Africa from country payer and societal perspectives. Deterministic and probabilistic sensitivity analyses were conducted to assess the impact of uncertainty in model inputs. RESULTS The human rotavirus, live, attenuated, oral vaccine (HRV) was associated with cost savings versus HBRV from both perspectives, and versus BRV-PV 1-dose vial from the societal perspective. In the cost-effectiveness analysis, HRV was estimated to avoid 1,107 home care rotavirus gastroenteritis (RVGE) events, 247 medical visits, 35 hospitalisations, and 4 RVGErelated deaths versus HBRV and BRV-PV. This translated to 73 quality-adjusted life years gained. HRV was associated with lower costs versus HBRV from both payer (−$3.9M) and societal (−$11.5M) perspectives and versus BRV-PV 1-dose vial from the societal perspective (−$3.8M), dominating those options. HRV was associated with higher costs versus BRV-PV 1-dose vial from the payer perspective and versus BRV-PV 2‑dose vial from both payer and societal perspectives (ICERs: $51,834, $121,171, and $16,717, respectively), exceeding the assumed cost-effectiveness threshold of 0.5 GDP per capita. CONCLUSION Vaccination with a 2-dose schedule of HRV may lead to better health outcomes for children in South Africa compared with the 3-dose schedule rotavirus vaccines.en_US
dc.description.departmentMedical Virologyen_US
dc.description.librarianam2024en_US
dc.description.sdgSDG-03:Good heatlh and well-beingen_US
dc.description.sponsorshipThis study was sponsored by GlaxoSmithKline Biologicals SA (Study identifier VEO-000364). Support for third-party writing assistance for this article, provided by Megan Thomas, Costello Medical, UK was funded by GSK in accordance with Good Publication Practice (GPP 2022) guidelines (https://www.ismpp.org/gpp-2022).en_US
dc.description.urihttps://www.springer.com/journal/40261en_US
dc.identifier.citationMohy, A., Page, N., Boyce, W. et al. 2023, 'Economic evaluation of rotavirus vaccination in children aged under five years in South Africa', Clinical Drug Investigation, vol. 43, pp. 851-863. https://DOI.org/10.1007/s40261-023-01312-4.en_US
dc.identifier.issn1173-2563 (print)
dc.identifier.issn1179-1918 (online)
dc.identifier.other10.1007/s40261-023-01312-4
dc.identifier.urihttp://hdl.handle.net/2263/95685
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.rights© The Author(s) 2023. This article is licensed under a Creative Commons Attribution- NonCommercial 4.0 International Licenseen_US
dc.subjectVaccinationen_US
dc.subjectDeathsen_US
dc.subjectChildrenen_US
dc.subjectSouth Africa (SA)en_US
dc.subjectRotavirusen_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.titleEconomic evaluation of rotavirus vaccination in children aged under five years in South Africaen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Mohy_Economics_2023.pdf
Size:
2.11 MB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
Mohy_EconomicsSuppl_2023.pdf
Size:
1.6 MB
Format:
Adobe Portable Document Format
Description:
Supplementary Material

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: